Table 1.
Characteristics of included cohort by previous cancer status.
| Character | No previous cancer N = 61,973 | With prior cancers N = 5582 | p-value |
|---|---|---|---|
| Age (median) | 68 years | 73 years | |
| Gender | <0.001 | ||
| Male | 31,786 (51.29%) | 3334 (59.73%) | |
| Female | 30,187 (48.71%) | 2248 (40.27%) | |
| Race | <0.001 | ||
| White | 49,511 (79.89%) | 4621 (82.78%) | |
| Black | 7666 (12.37%) | 663 (11.88%) | |
| AI/AN | 362 (0.58%) | 10 (0.18%) | |
| AP | 4284 (6.91%) | 286 (5.12%) | |
| Unknown | 150 (0.24%) | 2 (0.04%) | |
| Location | <0.001 | ||
| Head | 32,379 (52.25%) | 2899 (51.93%) | |
| Body | 7003 (11.30%) | 650 (11.64%) | |
| Tail | 7342 (11.85%) | 681 (12.20%) | |
| Pancreatic duct | 415 (0.67%) | 30 (0.54%) | |
| Other specified parts of pancreas | 727 (1.16%) | 66 (1.18%) | |
| Overlapping | 4501 (7.26%) | 400 (7.17%) | |
| Pancreas, NOS | 9606 (15.50%) | 856 (15.34%) | |
| Tumour Size | <0.001 | ||
| ≤2 cm | 4636 (7.48%) | 485 (8.69%) | |
| 2 < size ≤4 cm | 22,509 (36.32%) | 2267 (40.61%) | |
| >4 cm | 17,325 (27.96%) | 1546 (27.70%) | |
| Unknown | 17,503 (28.24%) | 1284 (23.00%) | |
| SEER stage | <0.001 | ||
| Localided | 4196 (6.77%) | 558 (10.00%) | |
| Regional | 20,872 (33.68%) | 1939 (34.74%) | |
| Distant | 34,475 (55.63%) | 2828 (50.66%) | |
| Unstaged | 2430 (3.92%) | 257 (4.60%) | |
| Histologic type | 0.004 | ||
| Adenocarcinoma | 55,125 (88.95%) | 4,895 (87.69%) | |
| Infiltrating duct carcinoma | 6848 (11.05%) | 687 (12.31%) | |
| Grade | <0.001 | ||
| G1 | 2807 (4.53%) | 251 (4.50%) | |
| G2 | 11,040 (17.81%) | 930 (16.66%) | |
| G3 | 10,654 (17.19%) | 842 (15.08%) | |
| G4 | 408 (0.66%) | 29 (0.52%) | |
| Unknown | 37,064 (59.81%) | 3530 (63.24%) | |
| Surgery | 0.798 | ||
| No | 49,825 (80.40%) | 4486 (80.37%) | |
| Yes | 11,783 (19.01%) | 1067 (19.12%) | |
| Unknown | 365 (0.59%) | 29 (0.52%) | |
| Radiation | <0.001 | ||
| None | 49,209 (79.40%) | 4591 (82.25%) | |
| Radiation | 12,265 (19.79%) | 941 (16.86%) | |
| Unknown | 499 (0.81%) | 50 (0.90%) | |
| Chemotherapy | <0.001 | ||
| No | 32,283 (52.09%) | 2765 (49.53%) | |
| Chemotherapy | 29,690 (47.91%) | 2817 (50.47%) |
AI/AN: American Indian/Alaska Native; AP: Asian or Pacific Islander; G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated; G4: undifferentiated; NOS: not otherwise specified; SEER: Surveillance, Epidemiology, and End Results.